TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBD
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Low-grade NMIBC
Conditions
Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, FGFR3 Gene Fusions
Trial Timeline
Jun 27, 2025 → Sep 1, 2028
NCT ID
NCT06995677About TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBD
TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBD is a phase 2 stage product being developed by Tyra Biosciences for Low-grade NMIBC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06995677. Target conditions include Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations.
What happened to similar drugs?
0 of 3 similar drugs in Low-grade NMIBC were approved
Approved (0) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06995677 | Phase 2 | Recruiting |
Competing Products
13 competing products in Low-grade NMIBC
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rabeprazole Sodium | Eisai | Pre-clinical | 26 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 42 |
| Everolimus | Novartis | Phase 2 | 35 |
| MEK162, MEK inhibitor; oral + Physician's choice chemotherapy | Pfizer | Phase 3 | 32 |
| Fludarabine Phosphate (Fludara) + Rituximab | Sanofi | Phase 2 | 35 |
| rituximab | Biogen | Phase 3 | 37 |
| Tovorafenib | Ipsen | Phase 1 | 33 |
| Tovorafenib | Day One Biopharmaceuticals | Phase 2 | 36 |
| Tovorafenib + Chemotherapeutic Agent | Day One Biopharmaceuticals | Phase 3 | 41 |
| DAY101 | Day One Biopharmaceuticals | Phase 1 | 23 |
| Tovorafenib | Day One Biopharmaceuticals | Pre-clinical | 20 |
| rhuFlt3L/CDX-301 + Poly-ICLC | Celldex Therapeutics | Phase 1/2 | 26 |
| combined therapy with rh-ES and CV | Brain Biotech | Phase 2 | 25 |